PlantExt

What PlantExt does

PlantEXT Ltd. is a Toronto-domiciled (Canadian parent of Israel Plant Sciences Limited), privately held pharmaceutical cannabis research and product development company founded in 2015. It develops proprietary, patent-pending cannabinoid and terpene formulations targeting inflammation-related medical conditions, including Inflammatory Bowel Disease (IBD), dermatology conditions (atopic dermatitis, psoriasis), chronic pain (arthritis, migraine), addiction disorders, and — as announced in October 2020 — COVID-19-related lung inflammation. Its core technology comprises non-strain-dependent synergistic combinations of cannabinoids and terpenes identified at the molecular level using an exclusively licensed methodology from Israel's Agricultural Research Organization (ARO) that quantifies anti-inflammatory activity on human biopsies; the company's lead IBD formulation demonstrated more than 2x the inflammation reduction of corticosteroid treatment in human biopsy studies.

The company's commercialization approach is B2B and licensing-oriented rather than direct-to-patient. PlantEXT monetizes through one-time licensing fees and royalty streams on its proprietary formulations, leveraging JV and licensing agreements with Family Secret (topical products), Panaxia/Rafa (suppositories), and exclusive global rights granted by the Government of the State of Israel. Its scientific credibility is anchored by an advisory board including Professor Raphael Mechoulam and by research leadership from Prof. Hinanit Koltai at ARO; operational leadership includes multiple TEVA Pharmaceuticals veterans and a former KPMG Global Chair as CEO. The company is small (1-10 employees), has raised approximately $7-8.2M in disclosed private financing (July 2019 private placement plus a separate 2019 round), and its planned 2019 Canadian public listing via BB1 Acquisition Corp. was terminated in January 2020. No revenue is publicly disclosed, and the most recent corporate signals date to late 2020.

Name

PlantExt

Legal name

PlantEXT Ltd.

Website

https://plantext.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

1–10 employees

Short description

PlantEXT Ltd. is a privately held Canadian-Israeli pharmaceutical cannabis R&D company developing proprietary, clinically evidenced cannabinoid formulations for inflammation-related conditions including IBD, dermatology, chronic pain, addiction, and COVID-19 lung inflammation, monetized via B2B licensing and joint ventures.

Ownership category

akta.pro rank

Product category

Cannabis Pharmaceuticals

NAICS

Medicinal and Botanical Manufacturing (325411), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Medicinal Chemicals & Botanical Products (2833), Pharmaceutical Preparations (2834)

akta.pro primary industry

Botanical & Herbal Extracts (Adaptogens, Polyphenols, Essential Oils, Standardized Extracts) (AFAJAKAD)

akta.pro secondary industries

Herbal & Botanical Supplements (CRADAGAD), Cannabis Dispensary + Pharmacy/Clinical Model (Patient Services) (CRANAFAI)

Keywords

• Medical cannabis formulations
• Cannabis pharmaceutical research
• Anti-inflammatory therapeutics
• Cannabis-based drug development
• Clinical cannabis products

Headquarters

HQ city

Toronto

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Medical Cannabis Product Sales: PlantEXT is developing and commercializing high profile, high margin and fast to market cannabis based medical products for inflammation-related conditions including IBD, dermatology, pain management, and addiction treatment.
2. Licensing Royalties: Exclusive global rights to commercialize ARO's intellectual property and products based on formulations of active cannabis compounds for treatment of various conditions.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

PlantExt develops and commercializes proprietary, patent-pending cannabis-based pharmaceutical formulations backed by clinical evidence for the treatment of inflammation-related medical conditions. Its portfolio targets Inflammatory Bowel Disease (IBD), dermatology conditions, chronic pain, addiction disorders, and COVID-19-related lung inflammation. The company generates revenue primarily through exclusive global licensing of its formulations and joint venture commercialization partnerships with pharmaceutical companies.

Product overview

PlantExt operates as a pharmaceutical cannabis research and product development company offering a pipeline of proprietary, patent-pending cannabis-based medical products targeting inflammation-related conditions. The portfolio consists of five core products: IBD (Inflammatory Bowel Disease) Formulations as the early-to-market clinically researched offering; Dermatology Products as all-natural topical cannabis medications; Pain Products combining CBD and terpenes for arthritis and migraine relief; Addiction Treatment R&D as a joint venture for endocannabinoid-based addiction therapy; and COVID-19 Lung Inflammation Treatment as a cannabis-based API targeting cytokine storm inflammation. The products share a foundation of proprietary cannabinoid and terpene formulations developed through a pharmaceutical Quality by Design approach, with effective delivery systems and clinical evidence-based validation.

Differentiator

Problem solved

Functional benefit

Products and services

• Inflammatory Bowel Disease (IBD) Formulations
• Dermatology Products All-natural medical skin care products representing the first generation of topical cannabis medications for inflammation-related dermatological conditions including Atopic Dermatitis and Psoriasis.
• Pain Products Combination of all-natural ingredients with CBD and terpenes designed to reduce pain for arthritis and migraine without pharmaceutical drug intervention.
• Addiction Treatment R&D Joint venture research program developing endocannabinoid-based treatments for addiction disorders using fatty acid amides, with patent applications filed across jurisdictions.
• COVID-19 Lung Inflammation Treatment Cannabis-based formulations targeting lung inflammation such as that provoked by COVID-19 cytokine storm, with anti-inflammatory activity identified in lung epithelial cell lines and macrophages; offered under exclusive global license from the Government of the State of Israel.

Quantifiable outcome

• More than 2x reduction in inflammation compared to corticosteroid treatment in human biopsy studies for IBD
• +1 more outcomes

Segments6 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Six partnerships are on record, tiered major and core.

• Panaxia and RafamajorStrategic or Co-development Partner · 1 May 2019Collaboration agreement to research and manufacture the first medical cannabis suppositories intended for patients suffering from inflammatory bowel disease (IBD, Crohn's and colitis).
• Family SecretmajorStrategic or Co-development Partner · 29 April 2019Joint venture agreement to develop, produce and market topical medical cannabis products. Family Secret brings expertise in topical cannabis formulations.
• Agricultural Research Organization (ARO) - IsraelcoreStrategic or Co-development PartnerPlantEXT has entered into a license agreement with ARO and funds research conducted by Dr. Hinanit Koltai, acquiring exclusive global rights to commercialize ARO's intellectual property, methodology to quantify anti-inflammatory activity on human biopsies, and patent for IBD composition.
• The Government of the State of IsraelcoreStrategic or Co-development PartnerLicense agreement with the Government of the State of Israel for exclusive global rights to commercialize ARO's intellectual property and products based on formulations of active cannabis compounds for treatment of lung inflammation including COVID-19.
• The Hebrew University, JerusalemcoreStrategic or Co-development PartnerCollaboration coordinated by Professor Raphael Mechoulam, inventor and scientific consultant. Prof. Mechoulam has been researching medical cannabis and the human endocannabinoid system for over 50 years, isolating CBD and THC compounds.
• 4 International Endocannabinoid System Research CentersmajorStrategic or Co-development PartnerJoint venture research collaboration between leading endocannabinoid system research centers in the United States, Canada, Europe, and Israel, working on R&D related to the endocannabinoid system and addiction treatment.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• GW Pharmaceuticals (Jazz Pharmaceuticals): GW Pharmaceuticals developed Epidiolex, the first FDA-approved plant-derived cannabinoid prescription drug (now owned by Jazz Pharmaceuticals). Direct precedent for the cannabinoid-to-pharma commercial pathway that PlantEXT is pursuing, though at vastly larger scale and capitalization.
• Arena Pharmaceuticals: Arena Pharmaceuticals (acquired by Pfizer in 2022) developed cannabinoid receptor-targeted therapies for inflammatory diseases. Represents the pharma-strategic-acquirer pathway for cannabinoid inflammation assets and validates the inflammation/endocannabinoid mechanism PlantEXT is pursuing.
• Canopy Growth Corporation: Canopy Growth operates a major medical cannabis division (Spectrum Therapeutics) and has pursued cannabis-based pharmaceutical R&D. Relevant as a broad incumbent in the medical-cannabis commercialization space where PlantEXT's IP could be licensed or partnered.
• Tilray Brands: Tilray is a large, publicly-traded cannabis company with a pharmaceutical division (Tilray Medical) producing GMP-certified medical cannabis products. Comparable as a medical-cannabis commercialization platform that PlantEXT's licensed formulations could be distributed through.

Direct peers

• Zynerba Pharmaceuticals: Zynerba develops synthetic cannabinoid transdermal therapies for rare neurological and inflammatory conditions (Fragile X syndrome, epilepsy). Comparable in targeting inflammation-related indications with cannabinoid-derived pharmaceuticals, though using synthetic rather than botanical cannabinoids.
• Panaxia Pharmaceutical Industries: Israeli pharmaceutical manufacturer of medical cannabis dosage forms (suppositories, topicals, sublingual). Already a JV partner of PlantEXT for IBD suppositories; operates in the same cannabinoid-pharma niche and shares the Israeli R&D ecosystem.
• Tetra Bio-Pharma: Tetra Bio-Pharma is a cannabinoid-derived pharmaceutical company developing prescription drugs and drug-device combinations targeting inflammation, pain, and oncology. Highly comparable business model and therapeutic overlap with PlantEXT's pipeline.
• Corbus Pharmaceuticals: Corbus Pharmaceuticals develops cannabinoid-derived drug candidates targeting inflammatory and fibrotic diseases (e.g., lenabasum). Closely comparable to PlantEXT in therapeutic focus (inflammation), cannabinoid-pharma positioning, and clinical-stage development approach.

Regional players

• ICAN Israel-Cannabis (InterCure/Canonic): Israeli-based medical cannabis producer with pharmaceutical-grade operations and research ties to Israeli academic institutions. Comparable regional player leveraging Israel's cannabinoid-research ecosystem that PlantEXT also relies upon through ARO.

Others

• Cannabis Growth Opportunity Corporation: An existing financial investor in PlantEXT and a cannabis-focused investment issuer. Comparable as a sector capital partner that understands the medical-cannabis investment thesis, though operating on the financial rather than operational side.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/plantext-ltd.
• Xx.com/plantext_ltd

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PlantExt